Vizgen

Vizgen, founded in 2019 , is a groundbreaking company in the Biotechnology and Health Care industries , with its headquarters in the United States . The company has recently received a significant $85.20M Series C investment on June 3, 2022 from some prominent investors including Arch Venture Partners, Tao Capital Partners, Northpond Ventures, Novalis LifeSciences, Sofina, Blue Water Life Science Advisors, and David Walt . Vizgen is focused on revolutionizing genomics through its innovative MERSCOPE™ platform, which integrates single-cell and high-plex spatial genomics analysis. The company is dedicated to pushing the boundaries of in situ single-cell spatial genomics, setting new standards in the field. The MERSCOPE Platform allows for massively multiplexed, genome-scale nucleic acid imaging with exceptional accuracy at subcellular resolution. This breakthrough technology facilitates transformative insights in various research domains such as oncology, immunology, neuroscience, infectious disease, developmental biology, and cell and gene therapy. Moreover, it plays a crucial role in accelerating drug discovery and development, establishing itself as an essential tool in these processes. Overall, Vizgen's pioneering approach and its cutting-edge technology have positioned the company at the forefront of spatial genomics, offering researchers unprecedented insights into biological systems that govern human health and disease within a spatial context.